Amidst some positive news from the World Health Organization (WHO) that both COVID-19 deaths and new cases have recently been on the wane, there are “three major threats” to the UN-led international equitable vaccine initiative, COVAX, that require urgent attention.
Briefing UN Member States on Thursday, WHO chief Tedros Adhanom Ghebreyesus drew attention to a $27 billion financing gap in the ACT Accelerator, which supports the development and equitable distribution of coronavirus tests, treatments and vaccines globally.
“The longer this gap goes unmet, the harder it becomes to understand why, given this is a tiny fraction of the trillions of dollars that have been mobilized for stimulus packages in G20 countries”, he said.
And third, Tedros underscored the need for “an urgent scale-up in manufacturing to increase the volume of vaccines” with “innovative partnerships” to include tech transfer, licensing and “other mechanisms to address production bottlenecks”.
COVID swells in Africa
Meanwhile, as Africa marks one year since its first COVID-19 case, on 14 February, WHO revealed that last month, the continent had witnessed a 40 per cent surge in COVID fatalities – pushing the death toll there towards 100,000.
“The increasing deaths from COVID-19 we are seeing are tragic, but are also disturbing warning signs that health workers and health systems in Africa are dangerously overstretched”, WHO Regional Director for Africa Matshidiso Moeti said at a virtual press conference.
At the same time, in the last 28 days, over 22,300 deaths were reported on the continent – a 3.7 per cent fatality rise – compared with nearly 16,000 deaths in the previous 28 days, which reflected a 2.4 per cent increase, according to WHO.
This mortality spike comes as Africa’s second wave which began in October, seems to have peaked on 6 January, having spread significantly faster and proven far more lethal.
WHO maintained that second wave cases surged far beyond the peak experienced in the first wave and health facilities have become overwhelmed.
“This grim milestone must refocus everyone on stamping out the virus”, said Dr. Moeti.
New strain, new challenges
At the same time, new contagious COVID-19 strains are spreading rapidly as Africa gears up for its largest-ever vaccination drive.
The variant known as B1.351, which was first identified in South Africa, has now been detected in eight African States, while the mutation initially identified in the United Kingdom, called B1.1.7, has been found in six countries on the continent.
“This is obviously very disappointing news, but the situation is very dynamic”, said Dr. Moeti. “While a vaccine that protects against all forms of COVID-19 is our biggest hope, preventing severe cases which overwhelm hospitals is crucial”.
This week South Africa said it would pause the roll-out of the Oxford/AstraZeneca vaccine citing a study indicating that it is less effective in battling the country’s dominant B1.351 strain.
Coordinated approach needed
WHO says there is an “urgent need” for a coordinated approach to variant surveillance and more evaluation to help decipher the potential impact they may have on vaccine effectiveness.
“The pandemic is far from over, and vaccines are just one crucial tool in our fight against the virus. We must boost investments and support for our health workers and health systems by sticking to mask wearing, regular hand cleaning and safe social distancing”, said Dr Moeti.
COVID-19: WHO expresses hope worst of Omicron wave is over
Omicron continues to sweep the world, but cases seem to have peaked in some countries, which gives the head of the World Health Organization (WHO) hope that the worst of this latest wave of COVID-19 is over.
The number of deaths remains stable, but the agency is concerned about the impact the variant is having on already exhausted health workers and overburdened health systems.
“I remain particularly concerned about many countries that have low vaccination rates, as people are many times more at risk of severe illness and death if they’re unvaccinated”, Tedros said.
Omicron may be less severe, but for the WHO chief “the narrative that it is mild disease is misleading, hurts the overall response and costs more lives.”
Tedros noted that the virus is circulating “far too intensely with many still vulnerable” and argued that, for many countries, the next few weeks remain critical.
Over the weekend, the UN-backed COVAX facility delivered its one-billionth dose of vaccine.
Tedros said he was proud of the milestone, but believes it’s essential to keep forging ahead with distributing shots fairly, across the world.
“Vaccines may be less effective at preventing infection and transmission of Omicron than they were for previous variants, but they still are exceptionally good at preventing serious disease and death”, he explained.
For him, immunization continues to be “key to protecting hospitals from becoming overwhelmed.”
Tracking the virus
The WHO chief also highlighted the importance of tracking new variants, like Omicron, in real time.
Tedros believes that the pandemic is “nowhere near over” and, with the incredible growth of Omicron, new variants are likely to emerge.
So far, more than 7 million whole genome sequences from 180 countries have been submitted to GISAID, a global mechanism that provides open access to genomic data and was initially set up to track flu.
Using all that data, new formulations of vaccines are being developed and assessed for how they perform against different strains.
Despite those efforts, Tedros is concerned that the world will enter “a second and even more destructive phase of vaccine inequity”, if it doesn’t change course.
For Tedros, the challenge, once again, is that high prices and limited supply means access is limited.
WHO is currently working with its partners in ACT-Accelerator to negotiate lower prices with manufacturers and ensure supply will be available for low- and middle-income countries.
Next week, the WHO Executive Board, which is made up of 34 Member States, will meet to discuss the world’s health challenges.
The pandemic will remain at the forefront, but Member States will also be discussing the devastating impact of the pandemic on other health issues, and how the backsliding can be stopped.
According to the WHO chief, the agency willbe working to accelerate progress on negotiations around a global pandemic accord.
Cervical Cancer Awareness
On a final note, Tedros noted that January is Cervical Cancer Awareness month.
In 2020, an estimated 604,000 women were diagnosed with cervical cancer worldwide and about 342, 000 women died from the disease.
The main cause of the disease is infection with high-risk types of human papillomavirus (HPV), an extremely common family of viruses that are transmitted through sexual contact.
There are, however, vaccines that protect against high-risk HPV types, which means it should be one of the most preventable and treatable forms of cancer.
On Monday, Serbia announced that this year,it will introduce a vaccination programme against HPV, joining the 116 nationswho already do it.
UN-backed COVAX mechanism delivers its 1 billionth COVID-19 vaccine dose
With a 1.1 million jab delivery in Rwanda this weekend, the World Health Organization’s multilateral initiative to provide equal access to vaccines for all reached the one billion milestone.
Along with the Coalition for Epidemic Preparedness Innovations (CEPI), the Vaccine Alliance GAVI, and partners, WHO has led the largest vaccine procurement and supply operation in history with deliveries to 144 countries to date.
According to a press release published on Sunday, as of 13 January 2022, out of 194 countries members of WHO, 36 have vaccinated less than 10% of their population, and 88 less than 40%.
“COVAX’s ambition was compromised by hoarding/stockpiling in rich countries, catastrophic outbreaks leading to borders and supply being locked. And a lack of sharing of licenses, technology, and know-how by pharmaceutical companies meant manufacturing capacity went unused”, the agency explained.
On 24 February 2021, Ghana became the first country in the world to receive vaccines through COVAX when 600,000 doses of the Oxford–AstraZeneca vaccine were delivered to Accra.
The work that remains
COVAX is currently working with governments, manufacturers and partners to ensure that when countries receive vaccines, they can get them to people quickly.
“The work that has gone into this (1 billion) milestone is only a reminder of the work that remains”, the UN’s health agency underscored.
They added that with updated vaccines in the pipeline, citizens should demand that governments and pharmaceutical companies share health tools globally and “bring an end to the death and destruction cycles of this pandemic, limit new variants and drive a global economic recovery”.
COVAX is one of three pillars of the Access to COVID-19 Tools (ACT) Accelerator, which was launched by WHO in April 2020 in response to the pandemic.
The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.
WHO recommends two new drugs to treat patients with COVID-19
The World Health Organization (WHO) on Thursday reccommended two new drugs to treat patients with COVID-19, one for patients with critical disease, and another deemed effective for non-severe cases.
The first drug, baricitinib, is a Janus kinase (JAK) inhibitor- a class of drugs used to treat autoimmune conditions, blood and bone marrow cancers, and rheumatoid arthritis.
According to the WHO Guideline Development Group, it is “strongly recommended” for patients with severe or critical disease in combination with corticosteroids.
The group of international experts based their recommendation on “moderate certainty evidence” that it improves survival and reduces the need for ventilation.
There was no observed increase in adverse effects.
The experts note that it has a similar effectas other arthritis drugs called interleukin-6 (IL-6) inhibitors. Because of that, when both drugs are available, they suggest choosing the best option based on cost, availability, and clinician experience.
It is not recommended to use both drugs at the same time.
The experts also advise against the use of two other JAK inhibitors (ruxolitinib and tofacitinib) for patients with severe or critical cases of COVID-19 infection.
According to them, trials undergone using these drugs failed to show any benefits arising using either drug,and suggested a possible increase in serious side effects with tofacitinib.
In the same update, WHO makes a conditional recommendation for the use of a monoclonal antibody known as sotrovimab in patients with non-severe cases.
According to them, the drug should only be administered to patients at the highest risk of hospitalisation. In those at lower risk, it onlyshowed “trivial benefits”.
A similar recommendation has been madepreviously, for another monoclonal antibody drug, casirivimab-imdevimab, and the experts say there is insufficient data to recommend one over the other.
For both, the effectiveness against new variants, like Omicron, is still uncertain.
The group will update their guidelines for monoclonal antibodies when more data becomes available.
These recommendations are based on new evidence from seven trials involving over 4,000 patients with non-severe, severe, and critical infections.
Developed by WHO with the methodological support of MAGIC Evidence Ecosystem Foundation, the guidelinesprovide trustworthy guidance and help doctors make better decisions with their patients.
According to the agency, the guidelines are useful in fast moving research areas, because they allow researchers to update evidence summaries as new information becomes available.
The latest guidance also updates recommendations for the use of interleukin-6 receptor blockers and systemic corticosteroids for patients with severe or critical COVID-19; conditional recommendations for the use of casirivimab-imdevimab (another monoclonal antibody treatment) in selected patients; and against the use of convalescent plasma, ivermectin and hydroxychloroquine, regardless of disease severity.
Afghanistan: 500,000 jobs lost since Taliban takeover
More than half a million people have lost or been pushed out of their jobs in Afghanistan since the Taliban...
World Economic Forum Annual Meeting rescheduled to 22-26 May
The World Economic Forum is pleased to announce that it will hold its Annual Meeting 2022 in Davos-Klosters, Switzerland, from...
COVID-19: WHO expresses hope worst of Omicron wave is over
Omicron continues to sweep the world, but cases seem to have peaked in some countries, which gives the head of...
In 2022, military rivalry between powers will be increasingly intense
“Each state pursues its own interest’s, however defined, in ways it judges best. Force is a means of achieving the...
Choosing the Best Engine Hoist for your Garage
An engine hoist is an extremely valuable piece of equipment. It will allow you to remove an engine from a...
Latin America Leaders See Opportunities for Economic and Social Growth in 2022
Despite the impact of the COVID-19 pandemic, Latin American leaders, speaking on the third day of the World Economic Forum’s...
Unrest in Kazakhstan Only Solidifies China-Russia Ties
The Russian-led military operation in Kazakhstan has presented an important test for Moscow’s ties with Beijing. In early January, Kazakhstan...
South Asia3 days ago
India’s open invitation to a nuclear Armageddon
Finance4 days ago
China: $1.9 Trillion Boost and 88M Jobs by 2030 Possible with Nature-Positive Solutions
Americas3 days ago
Sino-American confrontation and the Re-binarized world
East Asia3 days ago
The role of CPC in supporting leadership schools in democratic countries
Science & Technology2 days ago
Closing the Cyber Gap: Business and Security Leaders at Crossroads as Cybercrime Spikes
East Asia2 days ago
The Spirit of the Olympic Games and the Rise of China
Reports3 days ago
Nearly half of City GDP at Risk of Disruption from Nature Loss
Crypto Insights2 days ago
Metaverse Leading the Gaming Revolution: Are NFTs Truly the Future of the Industry?